Drugs Controller General of India (DCGI) approves the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer for market authorization. The Indian Serum Institute will produce this vaccine (SII). CEO of The Serum Institute of India Adar Poonawalla tweeted the information.
“For the first time, there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the DCGI, MoHFW_INDIA for granting approval today,” it read.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV.
Also Read: Suspected case of Monkeypox in Kerala, sample from UAE traveler sent for testing
The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15.
After the vaccine’s phase 3 findings were deemed to be adequate, suggestions were made.
Sources close to ANI said, “It is expected that vaccine will be launched in the market before the year-end. The qHPV will be India’s first indigenously vaccine against cervical cancer. The Pune-based Serum Institute of India has applied for market authorisation after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology to ensure its early availability in the country.”
For cervical cancer patients between the ages of 9 and 26 years old, the DCGI’s Subject Expert Committee on June 15 approved the locally produced quadrivalent human papillomavirus (qHPV) vaccination from Serum Institute.
Follow Medically Speaking on Twitter Instagram Facebook
